Status: Recruiting
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.
Participants needed: 392
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Updated: Jun 23, 2026Locations: 40
Eligibility criteria
Locally advanced and unresectable or metastatic HER2-positive advanced breast ca... [+9]
Patients with KRAS mutant aCRC who have KRAS G12R mutation, BRAFV600E mutation,... [+2]